Brokerages Set Plus Therapeutics, Inc. (NASDAQ:PSTV) Price Target at $5.80

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have received an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $5.80.

A number of equities research analysts have recently weighed in on the stock. Lake Street Capital began coverage on shares of Plus Therapeutics in a report on Tuesday, February 3rd. They issued a “buy” rating and a $2.00 price objective on the stock. Zacks Research cut Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 11th. Ascendiant Capital Markets lowered their price objective on Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, November 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating and set a $1.00 target price (down previously from $2.00) on shares of Plus Therapeutics in a research note on Friday, January 23rd.

Plus Therapeutics Price Performance

Shares of PSTV stock opened at $0.27 on Monday. Plus Therapeutics has a 1-year low of $0.16 and a 1-year high of $2.31. The firm has a market cap of $37.67 million, a PE ratio of -0.14 and a beta of 0.89. The company has a 50-day moving average of $0.45 and a two-hundred day moving average of $0.53.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of PSTV. Jane Street Group LLC acquired a new stake in Plus Therapeutics in the second quarter valued at about $41,000. Susquehanna International Group LLP acquired a new stake in shares of Plus Therapeutics in the 3rd quarter valued at approximately $46,000. Scientech Research LLC purchased a new stake in shares of Plus Therapeutics in the third quarter valued at approximately $100,000. Altium Capital Management LLC acquired a new position in Plus Therapeutics during the third quarter worth $628,000. Finally, Geode Capital Management LLC raised its position in Plus Therapeutics by 72.5% in the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after acquiring an additional 589,544 shares in the last quarter. 3.28% of the stock is currently owned by hedge funds and other institutional investors.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.